NEW YORK, Jan. 06, 2017 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of Arrowhead Pharmaceuticals, Inc. securities (NASDAQ:ARWR) from May 11, 2015 through November 8, 2016, both dates inclusive (the “Class Period”) of the important January 17, 2017 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for Arrowhead investors under the federal securities laws.
To join the Arrowhead class action, go to http://www.rosenlegal.com/cases-997.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, Defendants made materially false and misleading statements and/or failed to disclose that: (1) ARC-520, one of Arrowhead’s drug candidates for patients with chronic hepatitis B infection, was fatal at certain doses; (2) consequently, the U.S. Food & Drug Administration was unlikely to approve ARC-520 as a hepatitis B treatment; (3) Arrowhead had overstated the approval prospects and commercial viability of ARC-520; and (4) as a result, Arrowhead’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 17, 2017. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-997.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected]. Attorney Advertising. Prior results do not guarantee a similar outcome.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] [email protected] [email protected] www.rosenlegal.com


Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand
Chinese Universities with PLA Ties Found Purchasing Restricted U.S. AI Chips Through Super Micro Servers
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore
Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate
Apple Turns 50: From Garage Startup to AI Crossroads
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs
Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth
Bank of America's $72.5M Epstein Settlement: What You Need to Know
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 



